Sensely, a virtual medical assistant application for patient engagement and chronic disease monitoring, announced Tuesday the completion of an $8 million Series B financing led by Chengwei Capital with participation from Bioveda Ventures, Fenox Venture Capital, Mayo Clinic, and Stanford StartX.
“This funding will accelerate Sensely’s mission to provide efficient and affordable care to people around the world utilizing artificial intelligence and machine learning tools,” said Sensely’s founder and CEO Adam Odessky. “Supporting over 20 conditions and protocols, our healthcare solutions have achieved remarkable results regarding patient compliance, reduction of readmissions, and lowering of costs. The capital raised will allow us to serve our clinicians and patients much better as well as expand our presence in the US, UK, and international markets.”
Sensely’s application offers therapeutic help with expertise and empathy. Sensely has the unique ability to engage with both young and elderly patients over long periods of time providing chronic disease monitoring, companionship, and immediate access to appropriate clinical services. “With the world facing a shortage of nurses and physicians, we need artificially and clinically intelligent assistants. By making technology more personal and purposeful, we can offload low-value tasks from medical providers and have them focus on the more sick patients,” said Odessky.
Richard Gu of Chengwei Capital added, “Healthcare industry participants across the world today are facing challenges in improving patient satisfaction, meeting ever changing regulatory compliance requirements, controlling costs, and figuring out best ways to embrace the digital health transformation. Adam and the Sensely team have developed practical and cost-effective solutions by leveraging virtual assistant and AI technology. We are excited to partner with Sensely to scale their business to the next level.”